Malignant mixed Mullerian tumor

Search Trials
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
Status:
Completed
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Recurrent Uterine Corpus Sarcoma
Intervention(s):
IxabepiloneLaboratory Biomarker Analysis
Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
Status:
Completed
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Mixed Mullerian Tumors of the Uterus
Intervention(s):
GemcitabineOxaliplatinRadiation
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Status:
Completed
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Recurrent Uterine Corpus Sarcoma
Intervention(s):
Laboratory Biomarker AnalysisThalidomide
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
Status:
Completed
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Recurrent Uterine Corpus Sarcoma
Intervention(s):
Pazopanib Hydrochloride
Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO – PazoDoble –
Status:
Unknown status
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Relapsed or Metastatic Uterine Leiomyosarcomas or Carcinosarcomas
Intervention(s):
Pazopanib plus GemcitabinePazopanib

Connect. Empower. Inspire.